louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01441375: Sickle Cell Disease: A Retrospective Chart Review
Official title: Complications in Patients With Sickle Cell Disease and Utilization of Iron Chelation Therapy: A Retrospective Medical Records Review
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sickle Cell Anemia
Keywords: Sickle cell anemia
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2011-09-27
Enrollment: 261
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Sickle cell anemia

Brief summary: This study is a retrospective chart review of sickle cell patients and will include patients whom have received blood transfusions and those whom have not. Of the transfused patients, it will also include those whom have received chelation therapy and those whom have not.


Eligibility criteria: Inclusion Criteria:

1. Patients with a diagnosis of Sickle Cell Disease (SCD) and a confirmed genotype
2. Patients ≥ 16 years of age
3. Patients with ≥ 6 months of follow-up data available from first SCD treatment at the center after they reach 16 years old
4. At least one SF reading during a non-acute phase on or after the first SCD treatment at the center after they reach 16 years old

Exclusion Criteria:

1. Patients who participated in a clinical trial for an iron chelating medication or in a clinical trial for transfusions for SCD (1) within the six months before the index date or (2) during the patient observation period
2. Patients with sickle cell trait

Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Sickle cell complications
timeFrame: average of 5 years
Secondary outcomes:
measure: Utilization of health care delivery to treat sickle cell complications
timeFrame: average of 5 years
measure: Overall survival
timeFrame: average of 5 years
measure: Utilization of blood transfusions (patients with frequent transfusions only)
timeFrame: average of 5 years
measure: Burden of iron overload (patients with frequent transfusions only)
timeFrame: average of 5 years
measure: Utilization of Iron Chelation Therapies (ICTs) (patients receiving deferoxamine or deferasirox [Exjade®] only)
timeFrame: average of 5 years
Other outcomes:
Locations:
city: New Orleans
country: United States
facility: Tulane University
state: Louisiana
city: Memphis
country: United States
facility: Universit of Tennessee
state: Tennessee
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT05427175: Evaluation of the Effect of Narrowband UVB Versus Methotrexate on Serum Chitotriosidase Level in Psoriasis
Official title: Evaluation of the Effect of Narrowband Ultraviolet B Versus Methotrexate on Serum Chitotriosidase Level in Psoriasis.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Psoriasis
Lead sponsor: Aswan University Hospital
Sponsor class: OTHER
First posted: 2022-06-22
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to evaluate the effect of NB-UVB versus MTX on serum Chitotriosidase level in psoriatic patients.


Eligibility criteria: Inclusion Criteria:

* Patients with moderate to severe plaque psoriasis of any age and gender.

Exclusion Criteria:

* History of psoriasis treatment with systemic and biological agents prior to the study for at least 3 months.
* Pregnancy and lactation.
* Infections.
* Patients with chronic diseases: hepatic disorders, hematologic diseases, chronic renal failure or cancer.

Primary outcomes:
measure: Serum Chitotriosidase in psoriasis
timeFrame: 3 months
Secondary outcomes:
measure: Treatment of psoriasis
timeFrame: 3 months
Other outcomes:
Locations:
city: Aswan
country: Egypt
facility: Aswan University - Faculty of Medicine
state: Aswan Governorate, Egypt
Study officials:
affiliation: Faculty of medicine aswan university
name: Moustafa A El Taieb
role: STUDY_CHAIR
References:
Clinical trial NCT01553175: Studying Gene Expression in Samples From Patients With Rhabdoid Tumors
Official title: Determination of the Frequency of BRG1 and BRM Loss in Rhabdoid Tumors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Brain and Central Nervous System Tumors
Kidney Cancer
Keywords: childhood atypical teratoid/rhabdoid tumor
rhabdoid tumor of the kidney
Lead sponsor: Children's Oncology Group
Sponsor class: NETWORK
Collaborators: name: National Cancer Institute (NCI)
First posted: 2012-03-14
Enrollment: 25
Sex: ALL
Maximum age (years): 120
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with rhabdoid tumors

Brief summary: RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and find biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

PURPOSE: This research trial studies gene expression in samples from patients with rhabdoid tumors.

Detailed description: OBJECTIVES:

* To determine if BRM is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
* To determine if BRG1 is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
* To determine if GATA1 and/or HDAC2 is overexpressed in the same tumors that lack BRM expression.
* To determine if BRM promoter polymorphisms correlate with loss of BRM expression in primary rhabdoid tumors.
* To determine how BRG1 is silenced in primary rhabdoid tumors by sequencing BRG1 exons in genomic DNA derived from frozen samples.

OUTLINE: Archived tumor tissue samples are analyzed for BRM, BRG1, GATA1, and/or HDAC2 expression by immunohistochemistry. BRM- and BRG1-negative samples are also analyzed.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Tumor samples from patients diagnosed with rhabdoid tumors
* Matched frozen tumor tissue from BRG1-negative tumors (preferred) or matched genomic DNA from tumors, 100 ng per tumor from BRG1-negative tumors
* Any source of DNA from BRG1-negative tumors (tumors, blood, etc.)
* Matched frozen tumor tissue from BRM-negative tumors to confirm that BRM is not mutated or altered but rather epigenetically suppressed when lost in rhabdoid tumors

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

Primary outcomes:
measure: Absence or presence BRG1 and BRM expression in rhabdoid tumors
measure: Mechanism of suppression of BRG1 and BRM genes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Florida
name: David Reisman, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02520375: Effects of Prebiotic Oral Healthcare Products as an Adjunct to Non-surgical Periodontal Therapy
Official title: Effects of Prebiotic Oral Healthcare Products as an Adjunct to Non-surgical Periodontal Therapy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Periodontitis
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2015-08-11
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED

Brief summary: The aim of this study is to determine the impact of a prebiotic toothpaste and mouthrinse in periodontitis patients as an adjunct to scaling and rootplaning.

Detailed description: The aim of this study is to determine the impact of a prebiotic toothpaste and mouthrinse in periodontitis patients as an adjunct to scaling and rootplaning. Study design: this study will be a single centre (Department of Oral Health Sciences, University Hospitals Leuven), double blind, randomized, placebo controlled clinical trial. The randomization (by means of a computer program) and double blind design are thought to minimize the bias of the investigator and patients. Study population: adults, who consult at the department of Periodontology at the University Hospital Leuven and who fit the inclusion criteria will be asked to participate in this study.

Eligibility criteria: Inclusion Criteria:

* 40 patients
* ≥ 36 years of age

  - Page 4 of 4 \[DRAFT\] -
* No previous scaling and rootplaning
* Clinical diagnosis: severe generalized periodontitis characterized by the presence of \> 14 affected teeth when \> 14 teeth are present (if number of teeth present is \< 14, 8-14 teeth need to be affected) with an attachment loss of \> 6mm prior to initial non-surgical periodontal therapy.
* A minimum of 3 natural teeth in every quadrant
* Willing and able to give written informed consent

Exclusion Criteria:

* Patients with aggressive periodontitis or necrotizing periodontitis
* Patients who smoke
* Pregnant or lactating woman
* A history of diabetes, rheumatic fever, liver or kidney disease, neurological deficiencies, or use of medication which may affect periodontal tissue, (phenytoin, cyclosporin, nifedipine, chronic use of non-steroidal antiinflammatory drugs)
* Patients with poorly controlled diabetes
* Patients taking bisphosphonate mediation
* Patient who have taken systemic antibiotics 3 months prior to treatment

Primary outcomes:
measure: Pocket Probing Depth (PPD) at teeth with residual pockets
timeFrame: Baseline - 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04101175: Abortions at Strasbourg University Hospitals
Official title: A Survey of Best Practices of Abortions at Strasbourg University Hospitals
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: First-trimester Pregnancy
Keywords: First-trimester pregnancy
Abortions
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2019-09-24
Enrollment: 2000
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient in the first trimester of pregnancy wishing an abortion

Brief summary: The number of abortions in France and Strasbourg has been stable for several years. In 2017, 1847 were performed in the Gynecology-Obstetrics Department for 6146 deliveries (23% of all pregnancies). It therefore seems important to evaluate the professional practices, but also the experiences of the patients.


Eligibility criteria: Inclusion criteria:

* Patient in the first trimester of pregnancy wishing an abortion
* Age: greater than or equal to 18 years.
* Patient affiliated to a social security system

Exclusion criteria:

* Patient after the first trimester pregnancy
* Patient benefiting from a legal protection measure
* Bad understanding of French.

Primary outcomes:
measure: Evaluate the investigator's professional practices regarding abortion, particularly in relation to the recommendations for clinical practice of the National College of French Obstetricians Gynecologists (CNGOF) published in 2016.
timeFrame: 6 weeks
Secondary outcomes:
measure: Evaluation of the sociological, economic and psychological factors motivating the request for abortion
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Les Hôpitaux Universitaires de Strasbourg
Study officials:
References:
Clinical trial NCT03439475: AMG 714 Expanded Access Program
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Celiac Disease
Keywords: Refractory Celiac Disease Type II
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2018-02-20
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT

Brief summary: Expanded access requests for AMG 714 may be considered for adult patients with biopsy proven Refractory Celiac Disease Type II who have failed all available treatment options and do not have EATL. To request access, use Responsible Party contact information provided in this record.


Eligibility criteria: Inclusion Criteria:

-

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06342375: Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage
Official title: Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: No Medicaid Coverage
Keywords: Medicaid
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
Collaborators: name: Covering Wisconsin
First posted: 2024-04-02
Enrollment: 425000
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The goal of this study is to try new outreach methods to improve access to Medicaid for those who lost Medicaid for procedural reasons. The main questions it aims to answer are:

1. How does a live phone call from a Navigator impact Medicaid enrollment among people who lost Medicaid coverage for procedural reasons?
2. What is the effectiveness of outreach using a live call rather than a pre-recorded call?


Eligibility criteria: Inclusion Criteria:

* Eligible for Medicaid
* Lost Medicaid coverage between June 2024 and November 2025

Exclusion Criteria:

* Preferring a language other than English, Spanish, or Hmong
* No working phone number

Primary outcomes:
measure: Number of people who successfully renew their Medicaid coverage within 3 months of receiving the live outbound call
timeFrame: 3 months
Secondary outcomes:
measure: Duration of coverage gaps
timeFrame: 6 months
measure: Number of people who successfully renew their Medicaid coverage within 6 months of receiving the live outbound call
timeFrame: 6 months
measure: Number of people who successfully renew their Medicaid coverage within 6 months of receiving the pre-recorded outbound call
timeFrame: 6 months
Other outcomes:
Locations:
city: Madison
country: United States
facility: University of Wisconsin - Madison
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Rebecca Myerson, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03702075: Self-administered Program in Chronic Neck Pain
Official title: Effects of a Self-administered Program in Chronic Neck Pain Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Neck Pain
Keywords: chronic neck pain
Lead sponsor: Universidad de Granada
Sponsor class: OTHER
First posted: 2018-10-10
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Neck pain is a complex biopsychosocial disorder often precipitated or aggravated by neck movements or sustained neck postures. The onset and course of this pain are influenced by environmental and personal factors. Many studies report that participants preferred self-care measures for the management of neck pain and they sought professional help only when those measures fail.

Detailed description: Neck pain is the fourth leading cause of disability worldwide causing an enormous impact on individuals and their families, communities and healthcare systems.While neck pain can be severely disabling and costly, treatment options have shown moderate evidence of effectiveness. No previous study has used foam roller in patients with neck pain. In addition, it has been suggested that neurodynamic interventions provide a peripheral stimulus, reducing the pressure existing within the nerve, improving blood flow, axonal transport and nerve conduction. It was hypothesized that a self-administered intervention focused on myofascial release of main muscles related to neck pain and upper-limb active neurodynamics could reduce the presence of active trigger points and pain, improving functionality and active mobility.

Eligibility criteria: Inclusion Criteria:

* Chronic neck pain (at least 3 months' duration) not related to trauma of at least 3 on a visual analogue scale
* Participants' symptoms had to be reproduced by median nerve upper-limb neurodynamic test.

Exclusion Criteria:

* Exclusion Criteria:
* Whiplash related neck pain
* Previous cervical surgical intervention
* Cognitive impairments which prevent them to follow instructions
* Visual or acoustic limitations
* Physical therapy in the previous six months

Primary outcomes:
measure: Trigger points examination
timeFrame: Change from baseline trigger points examination at 4 weeks
Secondary outcomes:
measure: Pain severity
timeFrame: Change from baseline pain at 4 weeks
measure: Functionality
timeFrame: Change from baseline functionality at 4 weeks
measure: Cervical range of motion
timeFrame: Change from baseline cervical range of motion at 4 weeks
measure: Health related quality of life
timeFrame: Change from baseline health related quality of life at 4 weeks
measure: Fear avoidance beliefs
timeFrame: Change from baseline fear avoidance beliefs at 4 weeks
measure: Anxiety and depression
timeFrame: Change from baseline anxiety and depression at 4 weeks
Other outcomes:
Locations:
city: Granada.
country: Spain
facility: Faculty of Health Sciences. University of Granada.
state: Granada
Study officials:
References:
Clinical trial NCT07023575: Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions
Official title: Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Interstitial Lung Abnormalities
Keywords: interstitial lung abnormalities
Lead sponsor: China-Japan Friendship Hospital
Sponsor class: OTHER
First posted: 2025-06-17
Enrollment: 100000
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants were recruited from multiple health checkup centers across various regions of China between 2017 and 2024. Specifically, this retrospective study included data from 10 hospital-based health examination institutions located within the four major economic regions of China (East, Central, West, and Northeast). All available health examination records of individuals who underwent chest CT scans during this period were collected for analysis.

Brief summary: The goal of this observational study is to learn about the comorbidity patterns of interstitial and airway abnormalities in adults undergoing health examinations in China. The main questions it aims to answer are:

How do early interstitial lung abnormalities progress to comorbid interstitial and airway diseases? What are the key factors associated with this progression?

Participants undergoing routine health examinations will be assessed for interstitial and airway abnormalities based on imaging and clinical data. Longitudinal follow-up will be used to evaluate disease progression and identify associated risk factors.


Eligibility criteria: Inclusion Criteria:

* Underwent chest CT examination between January 1, 2017 and December 31, 2024
* Age 18 years or older at the time of examination

Exclusion Criteria:

- Missing or incomplete key demographic or imaging information (e.g., missing date of examination, sex, age, or CT report)

Primary outcomes:
measure: high-resolution computed tomography (HRCT) examinations
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: China-Japan Friendship Hospital
state: Beijing
city: Shanghai
country: China
facility: Zhongshan Hospital, Fudan University
state: Shanghai
city: Beijing
country: China
facility: Zhongguancun Meinian Health Industry Research Institute
city: Changsha
country: China
facility: Central South University
city: Guiyang
country: China
facility: Affiliated Hospital of Guizhou Medical University
city: Hangzhou
country: China
facility: Zhejiang University
city: Henan
country: China
facility: Henan Provincial People's Hospital
city: Qingdao
country: China
facility: The Affiliated Hospital of Qingdao University
city: Shenyang
country: China
facility: The First Affiliated Hospital of China Medical University
city: Xinxiang
country: China
facility: Henan Hongli Hospital Co., Ltd
Study officials:
References:
Clinical trial NCT03144375: QOL Outcomes in CRS With Polyps
Official title: Comparison of Outcomes After Peri-operative Optimization and Standard Surgical Treatment or Standard of Care Surgical Treatment in Patients Who Have Chronic Rhinosinusitis With Polyposis.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Chronic Rhinosinusitis, Polyps
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2017-05-08
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Chronic rhinosinusits (CRS) is common disease with reports of prevalence ranging from 4-16% in the western population. The main outcome measure for chronic disease treatment, such as CRS, is quality of life. Several large multi-institutional studies have shown that improvement in disease specific Quality of life was greater in patients who had surgery for their CRS with polyps. The timing of surgery in these patients has not been well studied but it is generally agreed upon that surgical candidates much had failed medical management. The definition of medical management varies greatly but usually includes some form of nasal or oral steroids and a prolonged ( \>10 days) course of antibiotics.

Another known way to improve QOL is through education and individualized optimization. This has been utilized successfully in other fields with good success and improved QOL. Similar studies looking at combining non-surgical optimization and education have not been performed in CRS. This study aims to address this potential area for improvement in patient quality of life outcomes. Investigators plan to assess the potential role for pre-operative non-surgical medical and educational optimization in CRS standard of care treatment.


Eligibility criteria: Inclusion Criteria:

* Adults with Rhinosinusitis with polyps who have had appropriate treatment qualifying them for surgery and are good surgical candidates

Exclusion Criteria:

* Cystic fibrosis, Cilia disorders, other specialized forms of sinus disease

Primary outcomes:
measure: SNOT-22
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
References: